ACRO Biomedical is in the leading position in providing collagen derived medical devices for the field of tissue engineering and regenerative medicine. The high end medical devices were processed by using supercritical carbon dioxide extraction technology to remove lipids, cells, and non-collagenous proteins from animal tissues and organs, to create natural collagen scaffolds as xenograft for various applications. The products can be applied to medical fields including Wound Care, Dentistry, Orthopedic, Ophthalmology, Aesthetic Microsurgery, Cardiology, and Neurosurgery. To date (Sep 2018), ACRO Biomedical has received 510(k) clearance on collagen matrix and bone graft products, and four TFDA certificates on collagen matrix, bone graft (two indication: orthopedics and dentistry) and collagen membrane. In addition, natural scaffolds derived from different tissues can be applied to various cell culture and tissue engineering application.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Cartilage graft and cornea
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):